首页 > 市场调查报告书 > 製药

呼吸器

市场调查报告书

商品编码

1392291

全球气喘生物製剂市场研究报告 - 2023 年至 2030 年产业分析、规模、份额、成长、趋势与预测

Global Asthma Biologics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

出版日期: 2023年11月01日 | 出版商:

Value Market Research | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球气喘生物製剂市场需求预计将从 2022 年的 72.9 亿美元增至 2030 年的近 201.6 亿美元，2023-2030 年研究期间CAGR为 13.56%。

气喘生物製剂是一种用于治疗气喘的药物，其特征是发炎和气道狭窄。与支气管扩张剂和皮质类固醇等传统气喘药物不同，生物製剂是一类新型药物，针对参与发炎反应的特定途径的免疫系统。

市场动态：

气喘生物製剂市场受到多种因素的推动，包括严重气喘盛行率的不断上升、生物技术的进步以及对个人化医疗的日益重视。对气喘病理生理学的了解不断加深，以及对更有效、更安全的治疗方法的渴望，推动了生物製剂的开发和采用。全球医疗保健支出的不断增长，加上监管部门批准的扩大，促进了市场的成长。随着患者和医疗保健专业人员意识的增强，人们越来越认识到生物製剂在治疗严重、不受控制的气喘方面的益处。市场的动态是由持续的研究、技术进步和对创新解决方案的追求决定的，反映了气喘治疗不断变化的格局。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球气喘生物製剂市场的各个细分市场进行了包容性评估。气喘生物製品产业的成长和趋势为本研究提供了整体方法。

区域分析：

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲气喘生物製品市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。气喘生物製剂市场的主要参与者包括安进公司、阿斯特捷利康公司、罗氏公司、葛兰素史克公司、诺华公司、再生元製药公司、赛诺菲公司、梯瓦製药工业有限公司等。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

区域展望
介绍
北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区国家/地区销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 8 章：气喘生物製剂公司的竞争格局

气喘生物製剂市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 9 章：公司简介

顶级公司市占率分析
市场集中度
Amgen Inc.

公司简介
公司收入
产品
最近的发展

AstraZeneca

公司简介
公司收入
产品
最近的发展

F. Hoffmann-La Roche Ltd.

公司简介
公司收入
产品
最近的发展

GSK plc

公司简介
公司收入
产品
最近的发展

Novartis AG

公司简介
公司收入
产品
最近的发展

Regeneron Pharmaceuticals Inc.

公司简介
公司收入
产品
最近的发展

Sanofi

公司简介
公司收入
产品
最近的发展

Teva Pharmaceutical Industries Ltd.

公司简介
公司收入
产品
最近的发展

Other

公司简介
公司收入
产品
最近的发展

注意 - 在公司概况中，财务详细资讯和近期发展视情况而定，或者如果是私人公司，则可能不包括在内

简介目录图表

Product Code: VMR112112800

The global demand for Asthma Biologics Market is presumed to reach the market size of nearly USD 20.16 BN by 2030 from USD 7.29 BN in 2022 with a CAGR of 13.56% under the study period 2023 - 2030.

Asthma biologics are a type of medication used in the treatment of asthma, which is characterized by inflammation and narrowing of the airways. Unlike traditional asthma medications such as bronchodilators and corticosteroids, biologics are a newer class of drugs that target the immune system at specific pathways that are involved in the inflammatory response.

MARKET DYNAMICS:

The asthma biologics market is propelled by several factors, including the escalating prevalence of severe asthma, advancements in biotechnology, and a growing emphasis on personalized medicine. The increased understanding of asthma pathophysiology and a desire for more effective and safer therapies have driven the development and adoption of biologics. The rising global healthcare expenditure, coupled with expanding regulatory approvals, contributes to the market's growth. As awareness among patients and healthcare professionals grows, there is greater recognition of the benefits of biologics in managing severe, uncontrolled asthma. The market's dynamics are shaped by ongoing research, technological progress, and the quest for innovative solutions, reflecting the evolving landscape of asthma treatment.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of asthma biologics. The growth and trends of asthma biologics industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the asthma biologics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

Selective Immuno-Suppressants
Interleukin Inhibitors
Others

By Distribution Channel

Retail Pharmacies
E-Commerce
Others

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Asthma Biologics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Asthma Biologics market include Amgen, Inc., AstraZeneca, F. Hoffmann-La Roche Ltd., GSK plc, Novartis AG, Regeneron Pharmaceuticals, Inc., Sanofi, Teva Pharmaceutical Industries Ltd., Other. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . ASTHMA BIOLOGICS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Class
- 3.7.2 Market Attractiveness Analysis By Distribution Channel
- 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL ASTHMA BIOLOGICS MARKET ANALYSIS BY DRUG CLASS

5.1 Overview by Drug Class
5.2 Historical and Forecast Data
5.3 Analysis by Drug Class
5.4 Selective Immuno-suppressants Historic and Forecast Sales by Regions
5.5 Interleukin Inhibitors Historic and Forecast Sales by Regions
5.6 Others Historic and Forecast Sales by Regions

6 . GLOBAL ASTHMA BIOLOGICS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

6.1 Overview by Distribution Channel
6.2 Historical and Forecast Data
6.3 Analysis by Distribution Channel
6.4 Retail Pharmacies Historic and Forecast Sales by Regions
6.5 E-commerce Historic and Forecast Sales by Regions
6.6 Others Historic and Forecast Sales by Regions

7 . GLOBAL ASTHMA BIOLOGICS MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1. Overview, Historic and Forecast Data Sales Analysis
- 7.3.2. North America By Segment Sales Analysis
- 7.3.3. North America By Country Sales Analysis
- 7.3.4. United State Sales Analysis
- 7.3.5. Canada Sales Analysis
- 7.3.6. Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1. Overview, Historic and Forecast Data Sales Analysis
- 7.4.2. Europe by Segment Sales Analysis
- 7.4.3. Europe by Country Sales Analysis
- 7.4.4. United Kingdom Sales Analysis
- 7.4.5. France Sales Analysis
- 7.4.6. Germany Sales Analysis
- 7.4.7. Italy Sales Analysis
- 7.4.8. Russia Sales Analysis
- 7.4.9. Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1. Overview, Historic and Forecast Data Sales Analysis
- 7.5.2. Asia Pacific by Segment Sales Analysis
- 7.5.3. Asia Pacific by Country Sales Analysis
- 7.5.4. China Sales Analysis
- 7.5.5. India Sales Analysis
- 7.5.6. Japan Sales Analysis
- 7.5.7. South Korea Sales Analysis
- 7.5.8. Australia Sales Analysis
- 7.5.9. South East Asia Sales Analysis
- 7.5.10. Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1. Overview, Historic and Forecast Data Sales Analysis
- 7.6.2. Latin America by Segment Sales Analysis
- 7.6.3. Latin America by Country Sales Analysis
- 7.6.4. Brazil Sales Analysis
- 7.6.5. Argentina Sales Analysis
- 7.6.6. Peru Sales Analysis
- 7.6.7. Chile Sales Analysis
- 7.6.8. Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1. Overview, Historic and Forecast Data Sales Analysis
- 7.7.2. Middle East & Africa by Segment Sales Analysis
- 7.7.3. Middle East & Africa by Country Sales Analysis
- 7.7.4. Saudi Arabia Sales Analysis
- 7.7.5. UAE Sales Analysis
- 7.7.6. Israel Sales Analysis
- 7.7.7. South Africa Sales Analysis
- 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE ASTHMA BIOLOGICS COMPANIES

8.1. Asthma Biologics Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9 . COMPANY PROFILES OF ASTHMA BIOLOGICS INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Amgen Inc.
- 9.3.1. Company Overview
- 9.3.2. Company Revenue
- 9.3.3. Products
- 9.3.4. Recent Developments
9.4. AstraZeneca
- 9.4.1. Company Overview
- 9.4.2. Company Revenue
- 9.4.3. Products
- 9.4.4. Recent Developments
9.5. F. Hoffmann-La Roche Ltd.
- 9.5.1. Company Overview
- 9.5.2. Company Revenue
- 9.5.3. Products
- 9.5.4. Recent Developments
9.6. GSK plc
- 9.6.1. Company Overview
- 9.6.2. Company Revenue
- 9.6.3. Products
- 9.6.4. Recent Developments
9.7. Novartis AG
- 9.7.1. Company Overview
- 9.7.2. Company Revenue
- 9.7.3. Products
- 9.7.4. Recent Developments
9.8. Regeneron Pharmaceuticals Inc.
- 9.8.1. Company Overview
- 9.8.2. Company Revenue
- 9.8.3. Products
- 9.8.4. Recent Developments
9.9. Sanofi
- 9.9.1. Company Overview
- 9.9.2. Company Revenue
- 9.9.3. Products
- 9.9.4. Recent Developments
9.10. Teva Pharmaceutical Industries Ltd.
- 9.10.1. Company Overview
- 9.10.2. Company Revenue
- 9.10.3. Products
- 9.10.4. Recent Developments
9.11. Other
- 9.11.1. Company Overview
- 9.11.2. Company Revenue
- 9.11.3. Products
- 9.11.4. Recent Developments